Fam-trastuzumab deruxtecan-nxki improves outcomes in gastric cancer subset

Fam-trastuzumab deruxtecan-nxki significantly improved outcomes compared with chemotherapy among patients with HER2-positive gastric cancer, according to study results presented during the ASCO20 Virtual Scientific Program.Results of the randomized phase 2 DESTINY-Gastric01 trial were published simultaneously in The New England Journal of Medicine.“Fam-trastuzumab deruxtecan-nxki [Enhertu; AstraZeneca, Daiichi Sankyo) is the first drug that has shown statistically significant and clinically meaningful improvement in response rate and OS [among patients with HER2-positive gastric cancer]Read More

Share on facebook
Share on twitter
Share on linkedin